Evidence map›Paper›PMID 28399885›Full record

ArticleJournal of hematology & oncology2017

Next-generation sequencing and FISH studies reveal the appearance of gene mutations and chromosomal abnormalities in hematopoietic progenitors in chronic lymphocytic leukemia.

Miguel Quijada-Álamo, María Hernández-Sánchez, Cristina Robledo, Jesús-María Hernández-Sánchez, Rocío Benito, Adrián Montaño, Ana E Rodríguez-Vicente, Dalia Quwaider, Ana-África Martín, María García-Álvarez and 15 more

Open access · goldAbstract read
In one paragraph

Article in Journal of hematology & oncology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed
4.2field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 47 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Review
  6. Review
  7. Article
  8. Review
  9. Review
  10. Review
  11. Review
  12. Pathogenesis of chronic lymphocytic leukemia and the development of novel therapeutic strategies.Journal of clinical and experimental hematopathology : JCEH · 2020
    Review
  13. Review
  14. FBW7 in hematological tumors.Oncology letters · 2020
    Review
  15. Review
  16. Review
  17. Article
  18. Article
  19. Annals of translational medicine · 2019
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors at 14 institutions in 3 countries.

Miguel Quijada-ÁlamoServicio de Hematología & IBSAL, IBMCC, CIC Universidad de Salamanca-CSIC, Hospital Universitario, Salamanca, Spain.
María Hernández-SánchezServicio de Hematología & IBSAL, IBMCC, CIC Universidad de Salamanca-CSIC, Hospital Universitario, Salamanca, Spain.
Cristina RobledoServicio de Hematología & IBSAL, IBMCC, CIC Universidad de Salamanca-CSIC, Hospital Universitario, Salamanca, Spain.
Jesús-María Hernández-SánchezServicio de Hematología & IBSAL, IBMCC, CIC Universidad de Salamanca-CSIC, Hospital Universitario, Salamanca, Spain.
Rocío BenitoServicio de Hematología & IBSAL, IBMCC, CIC Universidad de Salamanca-CSIC, Hospital Universitario, Salamanca, Spain.
Adrián MontañoServicio de Hematología & IBSAL, IBMCC, CIC Universidad de Salamanca-CSIC, Hospital Universitario, Salamanca, Spain.
Ana E Rodríguez-VicenteServicio de Hematología & IBSAL, IBMCC, CIC Universidad de Salamanca-CSIC, Hospital Universitario, Salamanca, Spain.
Dalia QuwaiderServicio de Hematología & IBSAL, IBMCC, CIC Universidad de Salamanca-CSIC, Hospital Universitario, Salamanca, Spain.
Ana-África MartínServicio de Hematología & IBSAL, IBMCC, CIC Universidad de Salamanca-CSIC, Hospital Universitario, Salamanca, Spain.
María García-ÁlvarezServicio de Hematología & IBSAL, IBMCC, CIC Universidad de Salamanca-CSIC, Hospital Universitario, Salamanca, Spain.
María Jesús Vidal-ManceñidoServicio de Hematología, Hospital Virgen Blanca, León, Spain.
Gonzalo Ferrer-GarridoServicio de Hematología, Hospital Miguel Servet, Zaragoza, Spain.
María-Pilar Delgado-BeltránServicio de Hematología, Hospital Miguel Servet, Zaragoza, Spain.
Josefina GalendeServicio de Hematología, Hospital del Bierzo, Ponferrada, León, Spain.
Juan-Nicolás RodríguezServicio de Hematología, Hospital Juan Ramón Jiménez, Huelva, Spain.
Guillermo Martín-NúñezServicio de Hematología, Hospital Virgen del Puerto, Plasencia, Cáceres, Spain.
José-María AlonsoServicio de Hematología, Hospital Río Carrión, Palencia, Spain.
Alfonso García de CocaServicio de Hematología, Hospital Clínico, Valladolid, Spain.
José A QueizánServicio de Hematología, Hospital General de Segovia, Segovia, Spain.
Magdalena SierraServicio de Hematología, Hospital Virgen de la Concha, Zamora, Spain.
Carlos AguilarServicio de Hematología, Hospital Santa Bárbara, Soria, Spain.
Alexander KohlmannMLL Munich, Munich, Germany.
José-Ángel HernándezServicio de Hematología, Hospital Universitario Infanta Leonor, Universidad Complutense de Madrid, Madrid, Spain.
Marcos GonzálezServicio de Hematología & IBSAL, IBMCC, CIC Universidad de Salamanca-CSIC, Hospital Universitario, Salamanca, Spain.
Jesús-María Hernández-RivasServicio de Hematología & IBSAL, IBMCC, CIC Universidad de Salamanca-CSIC, Hospital Universitario, Salamanca, Spain. jmhr@usal.es.
Instituto de Investigación Biomédica de Salamanca · ESUniversidad de Salamanca · ESCentro de Investigación del Cáncer · ESHospital Universitario Miguel Servet · ESAstraZeneca (United Kingdom) · GBHospital Clínico Universitario de Valladolid · ESHospital El Bierzo · ESHospital General De Segovia · ESHospital Juan Ramón Jiménez · ESHospital Rio Carrion · ESHospital Universitario Infanta Leonor · ESHospital Virgen de la Concha · ESHospital Virgen del Puerto · ESUniversity of Liverpool · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundChronic lymphocytic leukemia (CLL) is a highly genetically heterogeneous disease. Although CLL has been traditionally considered as a mature B cell leukemia, few independent studies have shown that the genetic alterations may appear in CD34+ hematopoietic progenitors. However, the presence of both chromosomal aberrations and gene mutations in CD34+ cells from the same patients has not been explored.

methodsAmplicon-based deep next-generation sequencing (NGS) studies were carried out in magnetically activated-cell-sorting separated CD19+ mature B lymphocytes and CD34+ hematopoietic progenitors (n = 56) to study the mutational status of TP53, NOTCH1, SF3B1, FBXW7, MYD88, and XPO1 genes. In addition, ultra-deep NGS was performed in a subset of seven patients to determine the presence of mutations in flow-sorted CD34+CD19- early hematopoietic progenitors. Fluorescence in situ hybridization (FISH) studies were performed in the CD34+ cells from nine patients of the cohort to examine the presence of cytogenetic abnormalities.

resultsNGS studies revealed a total of 28 mutations in 24 CLL patients. Interestingly, 15 of them also showed the same mutations in their corresponding whole population of CD34+ progenitors. The majority of NOTCH1 (7/9) and XPO1 (4/4) mutations presented a similar mutational burden in both cell fractions; by contrast, mutations of TP53 (2/2), FBXW7 (2/2), and SF3B1 (3/4) showed lower mutational allele frequencies, or even none, in the CD34+ cells compared with the CD19+ population. Ultra-deep NGS confirmed the presence of FBXW7, MYD88, NOTCH1, and XPO1 mutations in the subpopulation of CD34+CD19- early hematopoietic progenitors (6/7). Furthermore, FISH studies showed the presence of 11q and 13q deletions (2/2 and 3/5, respectively) in CD34+ progenitors but the absence of IGH cytogenetic alterations (0/2) in the CD34+ cells. Combining all the results from NGS and FISH, a model of the appearance and expansion of genetic alterations in CLL was derived, suggesting that most of the genetic events appear on the hematopoietic progenitors, although these mutations could induce the beginning of tumoral cell expansion at different stage of B cell differentiation.

conclusionsOur study showed the presence of both gene mutations and chromosomal abnormalities in early hematopoietic progenitor cells from CLL patients.

Indexed as

Chromosome AberrationsMutationAntigens, CD19Antigens, CD34Hematopoietic Stem CellsHigh-Throughput Nucleotide SequencingHumansIn Situ Hybridization, FluorescenceLeukemia, Lymphocytic, Chronic, B-CellAntigens, CD19Antigens, CD34CD19 molecule, humanChromosomal abnormalityChronic lymphocytic leukemiaFISHHematopoietic progenitorsMutationNext-generation sequencing

Identifiers

PMID28399885
PMCPMC5387353
OpenAlexW2606911185

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.